Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. more
Time Frame | AGIO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.1% | -2.12% | -3% |
1-Month Return | -35.15% | -3.42% | -0.73% |
3-Month Return | -23.91% | -11.13% | 2.87% |
6-Month Return | -16.56% | -5.74% | 7.17% |
1-Year Return | 53.6% | 3.97% | 25.31% |
3-Year Return | 4.7% | 1.05% | 28.38% |
5-Year Return | -27.1% | 34.37% | 81.89% |
10-Year Return | -70.67% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 117.91M | 203.20M | 41.41K | 14.24M | 26.82M | [{"date":"2019-12-31","value":58.03,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.02,"profit":true},{"date":"2022-12-31","value":7.01,"profit":true},{"date":"2023-12-31","value":13.2,"profit":true}] |
Cost of Revenue | 1.32M | 2.81M | 18.78M | 1.70M | 9.50M | [{"date":"2019-12-31","value":7.01,"profit":true},{"date":"2020-12-31","value":14.94,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":9.07,"profit":true},{"date":"2023-12-31","value":50.62,"profit":true}] |
Gross Profit | 116.59M | 200.39M | (18.78M) | 12.54M | 17.32M | [{"date":"2019-12-31","value":58.18,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-9.37,"profit":false},{"date":"2022-12-31","value":6.26,"profit":true},{"date":"2023-12-31","value":8.64,"profit":true}] |
Gross Margin | 98.88% | 98.62% | (45345.21%) | 88.03% | 64.57% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.73,"profit":true},{"date":"2021-12-31","value":-45857.41,"profit":false},{"date":"2022-12-31","value":89.03,"profit":true},{"date":"2023-12-31","value":65.3,"profit":true}] |
Operating Expenses | 542.93M | 516.54M | 378.42M | 401.58M | 408.81M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.14,"profit":true},{"date":"2021-12-31","value":69.7,"profit":true},{"date":"2022-12-31","value":73.97,"profit":true},{"date":"2023-12-31","value":75.3,"profit":true}] |
Operating Income | (426.33M) | (316.15M) | (378.42M) | (389.05M) | (391.49M) | [{"date":"2019-12-31","value":-42633300000,"profit":false},{"date":"2020-12-31","value":-31614900000,"profit":false},{"date":"2021-12-31","value":-37841800000,"profit":false},{"date":"2022-12-31","value":-38904700000,"profit":false},{"date":"2023-12-31","value":-39148700000,"profit":false}] |
Total Non-Operating Income/Expense | 29.72M | (4.61M) | 22.74M | 170.04M | 72.74M | [{"date":"2019-12-31","value":17.48,"profit":true},{"date":"2020-12-31","value":-2.71,"profit":false},{"date":"2021-12-31","value":13.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.78,"profit":true}] |
Pre-Tax Income | (411.47M) | (327.37M) | (356.51M) | (231.80M) | (352.09M) | [{"date":"2019-12-31","value":-41147200000,"profit":false},{"date":"2020-12-31","value":-32737000000,"profit":false},{"date":"2021-12-31","value":-35651000000,"profit":false},{"date":"2022-12-31","value":-23180100000,"profit":false},{"date":"2023-12-31","value":-35208800000,"profit":false}] |
Income Taxes | (14.86M) | 7.85M | (1.98B) | (157.25M) | 6.46M | [{"date":"2019-12-31","value":-189.36,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-25203.11,"profit":false},{"date":"2022-12-31","value":-2003.64,"profit":false},{"date":"2023-12-31","value":82.25,"profit":true}] |
Income After Taxes | (396.61M) | (335.22M) | 1.62B | (74.56M) | (358.54M) | [{"date":"2019-12-31","value":-24.46,"profit":false},{"date":"2020-12-31","value":-20.67,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4.6,"profit":false},{"date":"2023-12-31","value":-22.11,"profit":false}] |
Income From Continuous Operations | (411.47M) | (309.54M) | (356.51M) | (231.80M) | (352.09M) | [{"date":"2019-12-31","value":-41147200000,"profit":false},{"date":"2020-12-31","value":-30953800000,"profit":false},{"date":"2021-12-31","value":-35651000000,"profit":false},{"date":"2022-12-31","value":-23180100000,"profit":false},{"date":"2023-12-31","value":-35208800000,"profit":false}] |
Income From Discontinued Operations | 1.96B | 1.96B | 1.96B | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (396.61M) | (335.22M) | 1.60B | (74.56M) | (352.09M) | [{"date":"2019-12-31","value":-24.72,"profit":false},{"date":"2020-12-31","value":-20.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4.65,"profit":false},{"date":"2023-12-31","value":-21.94,"profit":false}] |
EPS (Diluted) | (6.87) | (4.74) | 22.21 | (4.24) | (6.34) | [{"date":"2019-12-31","value":-30.93,"profit":false},{"date":"2020-12-31","value":-21.34,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-19.09,"profit":false},{"date":"2023-12-31","value":-28.55,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AGIO | |
---|---|
Cash Ratio | 8.41 |
Current Ratio | 8.99 |
Quick Ratio | 8.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AGIO | |
---|---|
ROA (LTM) | -18.18% |
ROE (LTM) | 53.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AGIO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AGIO | |
---|---|
Trailing PE | 3.07 |
Forward PE | 2.47 |
P/S (TTM) | 62.13 |
P/B | 1.37 |
Price/FCF | NM |
EV/R | 38.98 |
EV/Ebitda | NM |
PEG | NM |
Agios Pharm (AGIO) share price today is $35.42
Yes, Indians can buy shares of Agios Pharm (AGIO) on Vested. To buy Agios Pharm from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AGIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Agios Pharm (AGIO) via the Vested app. You can start investing in Agios Pharm (AGIO) with a minimum investment of $1.
You can invest in shares of Agios Pharm (AGIO) via Vested in three simple steps:
The 52-week high price of Agios Pharm (AGIO) is $62.58. The 52-week low price of Agios Pharm (AGIO) is $20.96.
The price-to-earnings (P/E) ratio of Agios Pharm (AGIO) is 3.3465
The price-to-book (P/B) ratio of Agios Pharm (AGIO) is 1.37
The dividend yield of Agios Pharm (AGIO) is 0.00%
The market capitalization of Agios Pharm (AGIO) is $2.23B
The stock symbol (or ticker) of Agios Pharm is AGIO